Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1696 to 1710 of 7681 results

  1. Dimethyl fumarate for treating relapsing-remitting multiple sclerosis in people aged 13 to 17 TS ID 11778

      Status ...

  2. CT-P43 (ustekinumab biosimilar) for treating moderate to severe plaque psoriasis TS ID 11773

      Status ...

  3. Selinexor for treating unresectable dedifferentiated advanced liposarcoma [ID3825]

    Awaiting development [GID-TA10694] Expected publication date: TBC

  4. Dusquetide for treating oral mucositis during chemoradiation for head and neck cancer [ID3830]

    Awaiting development [GID-TA10715] Expected publication date: TBC

  5. Lurbinectedin for treating advanced platinum-resistant ovarian cancer ID1340

    In development [GID-TA10313] Expected publication date: TBC

  6. Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]

    Awaiting development [GID-TA10723] Expected publication date: TBC

  7. Advocacy services for adults with health and social care needs

    Awaiting development [GID-QS10145] Expected publication date: TBC

  8. Supporting independent living and preventing isolation in adults of working age with social care needs

    Awaiting development [GID-QS10149] Expected publication date: TBC

  9. Total hip arthroplasty using the superpath approach for osteoarthritis

    In development [GID-IPG10204] Expected publication date: TBC

  10. Plinabulin with docetaxel for previously treated advanced non-small-cell lung cancer [ID3895]

    Awaiting development [GID-TA10776] Expected publication date: TBC

  11. Timrepigene emparvovec for treating choroideremia [ID3916]

    Awaiting development [GID-TA10787] Expected publication date: TBC

  12. Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction [ID3912 ]

    Awaiting development [GID-TA10797] Expected publication date: TBC

  13. Inolimomab (Leukotac) for acute Graft versus host disease (aGvHD) after Allo-HSCT [ID3923]

    Awaiting development [GID-TA10823] Expected publication date: TBC

  14. NY-ESO-1 T-cells for treating synovial sarcoma ID1286

    In development [GID-TA10205] Expected publication date: TBC